Table 1 For each sub-group (PROM or SPL), a response from 3700 babies will allow the following differences to be detected with 80% power:
Outcome | Incidence in erythromycin group | Incidence in erythromycin placebo group | Relative risk reduction |
|---|---|---|---|
'3 or more attributes affected' | 3.1% | 5% | 38% |
| Â | 5.6% | 8% | 30% |
| Â | 1.5% | 3% | 50% |